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Abstract
Stroke remains one of the most common causes of death and disability worldwide. Several preclinical studies demonstrated 
that the brain can be effectively protected against ischaemic stroke by two seemingly distinct treatments: remote ischae-
mic conditioning (RIC), involving cycles of ischaemia/reperfusion applied to a peripheral organ or tissue, or by systemic 
administration of glucagon-like-peptide-1 (GLP-1) receptor (GLP-1R) agonists. The mechanisms underlying RIC- and 
GLP-1-induced neuroprotection are not completely understood. In this study, we tested the hypothesis that GLP-1 mediates 
neuroprotection induced by RIC and investigated the effect of GLP-1R activation on cerebral blood vessels, as a potential 
mechanism of GLP-1-induced protection against ischaemic stroke. A rat model of ischaemic stroke (90 min of middle cerebral 
artery occlusion followed by 24-h reperfusion) was used. RIC was induced by 4 cycles of 5 min left hind limb ischaemia 
interleaved with 5-min reperfusion periods. RIC markedly (by ~ 80%) reduced the cerebral infarct size and improved the 
neurological score. The neuroprotection established by RIC was abolished by systemic blockade of GLP-1R with a specific 
antagonist Exendin(9–39). In the cerebral cortex of GLP-1R reporter mice, ~ 70% of cortical arterioles displayed GLP-1R 
expression. In acute brain slices of the rat cerebral cortex, activation of GLP-1R with an agonist Exendin-4 had a strong 
dilatory effect on cortical arterioles and effectively reversed arteriolar constrictions induced by metabolite lactate or oxygen 
and glucose deprivation, as an ex vivo model of ischaemic stroke. In anaesthetised rats, Exendin-4 induced lasting increases 
in brain tissue  PO2, indicative of increased cerebral blood flow. These results demonstrate that neuroprotection against 
ischaemic stroke established by remote ischaemic conditioning is mediated by a mechanism involving GLP-1R signalling. 
Potent dilatory effect of GLP-1R activation on cortical arterioles suggests that the neuroprotection in this model is mediated 
via modulation of cerebral blood flow and improved brain perfusion.
Keywords  Brain arterioles · Brain capillaries · Cerebral blood flow · Glucagon-like peptide-1 · Ischaemic stroke · Middle 
cerebral artery occlusion · Neuroprotection · Remote ischaemic preconditioning
Introduction
Stroke remains one of the most common causes of death 
and disability worldwide [42]. Interventions to restore 
cerebral blood flow to the viable tissue surrounding the 
infarct core, called the penumbra, are efficient if applied 
within hours after the stroke onset and limited to a large 
artery clot removal by intravenous thrombolysis or inva-
sive mechanical thrombectomy [74]. Many smaller ves-
sels, however, remain constricted and contribute to the no-
reflow phenomenon after stroke. This highlights the need 
for the development of novel therapies that can effectively 
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improve/restore the microvascular flow and salvage viable 
brain tissue from permanent ischaemic damage [4].
Our body is capable of recruiting powerful innate 
mechanisms of inter-organ protection against ischaemia/
reperfusion injury. These mechanisms effectively protect 
the heart and the brain and can be activated by cycles of 
ischaemia/reperfusion applied to an organ or tissue remote 
to the organ being protected. This well-characterized phe-
nomenon is called remote ischaemic conditioning (RIC) 
[23, 31, 33, 39, 47]. More than 40 preclinical studies dem-
onstrated that RIC can protect the brain against ischae-
mic stroke [14, 49, 72, 84]. Results of clinical studies 
[37] demonstrated that RIC improves brain perfusion, as 
well as visual-spatial and executive functions in patients 
affected by cerebral small vessel disease [83]. However, 
the mechanisms of RIC-induced neuroprotection are not 
fully understood and have been proposed to include reduc-
tion of astrogliosis, maintenance of blood–brain barrier 
integrity, the opening of  KATP channels, prevention of let-
7a and miR-43 overexpression, and other mechanisms [15, 
20, 48, 69, 70, 77, 82].
Previous studies on the mechanisms of RIC-induced 
cardioprotection against ischaemia/reperfusion injury sug-
gested that RIC recruits interacting neuronal and humoral 
mechanisms [8, 24, 26, 52, 75]. Our studies showed that 
these include sensory (afferent) innervation of the peripheral 
tissue undergoing RIC, autonomic parasympathetic (vagal) 
pathways, and the actions of an incretin hormone glucagon-
like-peptide-1 (GLP-1), as a likely humoral mediator of RIC 
[5, 6, 62, 63]. We hypothesised, therefore, that GLP-1 may 
also mediate RIC-induced neuroprotection against ischaemic 
stroke.
GLP-1 is an important hormone that has multiple func-
tions from the regulation of insulin secretion to the control of 
satiety and modulation of autonomic nervous system activity 
[2, 34–36]. GLP-1 is released by the enteroendocrine cells 
in the gut and also by the groups of specialized CNS neu-
rons located in the brainstem [35, 66]. Experimental studies 
conducted in gerbils, mice and rats demonstrated that GLP-1 
receptor (GLP-1R) agonists Exendin 4 (Ex4), liraglutide or 
semaglutide, administered either systemically or centrally, 
are highly effective in protecting the brain against ischaemic 
stroke induced by bilateral carotid artery occlusion or mid-
dle cerebral artery occlusion [9, 21, 50, 59, 78]. In at-risk 
diabetic patients, semaglutide was shown to significantly 
decrease the incidences of non-fatal strokes [60, 61]. How-
ever, the mechanisms underlying GLP-1R-mediated neuro-
protection remain largely unknown [19, 59].
In this study, we tested the hypothesis that GLP-1 medi-
ates neuroprotection induced by RIC. First, we determined 
the effect of GLP-1R blockade on RIC-induced neuroprotec-
tion, and then investigated the expression of GLP-1R and 
the effects of GLP-1R activation on cerebral blood vessels 
and brain blood flow, as a potential mechanism of GLP-
1R-mediated neuroprotection against ischaemic stroke.
Methods
All animal experiments were performed in accordance with 
the European Commission Directive 2010/63/EU (European 
Convention for the Protection of Vertebrate Animals used 
for Experimental and Other Scientific Purposes) and the UK 
Home Office (Scientific Procedures) Act (1986) with project 
approval from the University College London Institutional 
Animal Care and Use Committee. The study was designed 
and performed, the data analysed and reported in accord 
with the ARRIVE guidelines. Animals were maintained on 
a 12-h light/dark cycle and had ad libitum access to food 
and water.
Models of ischaemic stroke and remote ischaemic 
conditioning in rats
The experiments were conducted in male Sprague–Dawley 
rats (220-250 g) (n = 39). The animals underwent surgery to 
allow transient middle cerebral artery occlusion (MCAO) 
to induce cerebral ischaemia, as an experimental model of 
stroke [76]. Rats were anaesthetised with isoflurane (4% 
induction, 2% maintenance) and the right common carotid 
artery was exposed. A size-matched silicon-coated monofila-
ment (Doccol Corporation) was advanced through the right 
common and internal carotid arteries towards the middle 
cerebral artery junction until the resistance was met (dis-
tance ~ 2 cm). The wound was closed by removable stitches, 
analgesia was administered (Vetergesic, 0.01 mg  kg−1, i.p.), 
and the animals were placed in a heated recovery chamber. 
The animals were allowed to recover from anaesthesia to 
determine the presence of the functional signs of cortical 
ischaemia, including walking towards the contralateral side, 
left forelimb flexion and body rotation to the left when the 
animal was held by the tail. Animals not displaying these 
signs were excluded from the study. After 75 min of MCAO, 
the animals were re-anaesthetised with isoflurane and placed 
on a servo-controlled heating pad (body temperature main-
tained at 37 ± 0.5 °C). After 80 min of MCAO, sham-RIC 
or RIC was applied. The wound was re-opened to expose 
the carotid arteries, the MCA occluder was withdrawn 
90 min after the onset of ischaemia, the common carotid 
artery was ligated, and the wound was closed by suturing. 
The animals were placed in a recovery chamber until their 
complete recovery, before returning to their home cages.
The animals were randomized into four experimental 
groups: (1) rats with MCAO/sham-RIC; (2) rats subjected 
to RIC starting 10 min before the onset of reperfusion; RIC 
protocol involved 4 cycles of 5 min left hind limb ischaemia 
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interleaved with 5-min reperfusion periods [10, 29], applied 
using an inflatable 12-mm cuff (IVM, USA). The cuff was 
inflated to 200 mmHg to stop the blood flow through the 
limb, as reported previously [12]; (3) rats with MCAO 
treated with a competitive GLP-1R antagonist Exendin 
(9–39) (Ex9, 50 μg  kg−1, intravenously) 20 min before the 
onset of reperfusion; (4) rats subjected to the RIC protocol 
starting 10 min before the onset of reperfusion and treated 
with Ex9 10 min prior to the first episode of RIC. Experi-
mental timeline is illustrated by Fig. 1a.
Twenty four hours after MCAO, all animals underwent 
behavioural neurological assessment using the 0–22 scale, 
as described in detail previously [9, 79]. The principal points 
of the functional status evaluation were spontaneous activity, 
gait, postural signs, lateral resistance, limb placing, and par-
achute reflex. Higher neuroscores indicated more severe neu-
rological deficits. The rats were then euthanized with sodium 
pentobarbital overdose (200 mg  kg−1, i.p.). The brains were 
immediately removed, sectioned at 1.25-mm thickness, 
stained with 1% triphenyl tetrazolium chloride (TTC) and 
fixed in formalin. The sections were photographed, and the 
infarct areas were determined by computerized planimetry 
(Image J). Infarct sizes (IS) are presented as percentages of 
the hemispheric volume (%HLV). Functional status evalu-
ation and IS measurements were performed by the investi-
gator blinded to the experimental animal group allocation.
Acute brain slice preparation
Young Sprague–Dawley rats (P21 of either sex) were 
humanely killed by cervical dislocation, the brains were 
removed and placed in ice-cold artificial cerebrospinal fluid 
(aCSF) containing 124 mM NaCl, 26 mM  NaHCO3, 3 mM 
KCl, 2 mM  CaCl2, 1.25 mM  NaH2PO4, 11 mM  MgSO4, 
10 mM glucose saturated with 95%  O2/5%  CO2 (pH 7.4). 
Coronal cortical slices (thickness 300 µm) were cut using a 
vibratome and then incubated at room temperature for 1 h in 
a standard aCSF solution containing 1 mM  Mg2+ saturated 
with 95%  O2/5%  CO2.
Recordings of cerebrovascular responses
Recordings were made from slices placed on an elevated 
grid in a flow chamber at ~ 32 °C (flow 2 ml  min−1). Cortical 
arterioles and capillaries were identified by the diameter of 
the vessel (arterioles > 10 µM; capillaries < 10 µM) and the 
presence of smooth muscle, as described [64]. Brightfield 
imaging recordings of cerebrovascular responses induced 
by experimental treatments were performed using a Zeiss 
Axioskop 2 upright microscope with a 40 × water immer-
sion objective and a Hamamatsu CCD camera. Images were 
acquired every 30 s and vessel diameter changes were meas-
ured using ImageJ. The percentage change in vessel diameter 
from the baseline was calculated and the last 5 min of vessel 
diameter recordings from each group was averaged for com-
parison. Lactate (5 mM) was added to the perfusate to con-
strict the vessels. Lactate was used as a constricting agent 
because the release of this metabolite markedly increases in 
hypoxic and ischaemic conditions [43, 44, 57]. The model 
of brain ischaemia was induced by oxygen/glucose depriva-
tion (OGD). OGD was induced by exposing the slices to 
aCSF saturated with 95%  N2/5%  CO2 gas mixture contain-
ing 7 mM sucrose, replacing glucose. The rate of aCSF flow 
through the chamber was increased to 4 ml  min−1 (to reduce 
the time for gas exchange between the media and the atmos-
phere) and the period of OGD lasted for 25 min. Exendin-4 
(Ex4; 100 nM, Tocris) was used as GLP-1R agonist. Ex9 
(1 µM, Cohesion Biosciences) was used to block GLP-1Rs. 
N(gamma)-nitro-l-arginine methyl ester (l-NAME; 100 μM, 
Sigma) was used to inhibit nitric oxide synthesis. Adenylate 
cyclase was blocked with SQ22536 (100 μM, Tocris).
Measurements of brain tissue  PO2 in vivo
Young male rats (200–250  g; n = 11) were anaesthe-
tised with urethane (initial dose, 1.3  g   kg−1, i.p.; then 
10–25 mg  kg−1  h−1, i.v.). Adequate anaesthesia was ensured 
by maintaining stable levels of arterial blood pressure and 
heart rate, showing lack of responses to a paw pinch. The 
body temperature was maintained at 37 ± 0.5 °C. The femo-
ral artery and vein were cannulated for measurement of the 
arterial blood pressure and administration of anaesthetic, 
respectively. The trachea was cannulated, and the animal 
was ventilated with room air using a positive pressure ven-
tilator with a tidal volume of ∼1 ml 100  g−1 and a ventilator 
frequency similar to the resting respiratory rate (∼60 strokes 
 min−1). The animal was then placed in a stereotaxic frame 
and a small craniotomy (~ 1 mm in diameter) was made in 
the parietal bone. Brain tissue  PO2 was recorded in the left 
cerebral cortex using optical probes (250 μm tip diameter; 
OxyLite system; Oxford Optronix) placed ~ 2 mm below the 
surface of the brain, as described previously [58]. The opera-
tion of the sensor is based on fluorescence technology that 
allows real-time recordings of tissue  PO2. In urethane-anaes-
thetised rats, changes in brain tissue  PO2 parallel changes in 
cerebral blood flow [18], and were used in this study as a 
robust proxy measure of brain perfusion.
Immunohistochemistry
Mice expressing fluorescently tagged GLP-1R (Glp1r-cre/
tdRFP) [16, 71] were used to determine the expression of 
the receptor by the brain blood vessels. The animals were 
terminally anaesthetised with sodium pentobarbital over-
dose (200 mg  kg−1; i.p.) and perfused through the heart with 
0.01 M phosphate-buffered saline. The brains were removed 
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Fig. 1  GLP-1 receptors mediate neuroprotection against ischaemic 
stroke established by remote ischaemic conditioning. a Illustration 
of the experimental protocols. In rats, ischaemic stroke was induced 
by 90  min of middle cerebral artery occlusion (MCAO) followed 
by 24  h of reperfusion. Remote ischaemic conditioning (RIC) was 
established following 4 cycles of 5-min left hind limb ischaemia 
interleaved by 5-min reperfusion periods. Arrows indicate the time 
(20  min before the onset of reperfusion and/or 10  min prior to the 
application of the first RIC cycle) of intravenous administration of 
GLP-1 receptor antagonist Exendin(9–39) (Ex9). b Representa-
tive images of TTC-stained coronal brain sections from four experi-
mental groups 24  h after MCAO. c, d Summary data illustrating 
the effect of RIC on brain infarct size and behavioural neurological 
traits 24  h after MCAO. Neuroprotection induced by RIC was pre-
vented by systemic GLP-1 receptor blockade with Ex9. Infarct size 
is presented as a percentage of the hemispheric lesion volume (HLV). 
MCAO group, n = 7; MCAO + RIC group, n = 8; MCAO + Ex9 group, 
n = 7; and MCAO + Ex9/RIC group, n = 8 rats. Individual data and 
means ± SEM are shown. p values—ANOVA followed by Sidak’s 
correction for multiple comparisons
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and fixed overnight in 4% paraformaldehyde. Free-floating 
sections (20 µm thickness) were incubated (overnight at 
4 °C) with anti-DsRed antibody (1:500) (Takara Bio) to 
detect GLP-1R expressing cells and anti-smooth muscle 
actin (SMA) antibody conjugated to FITC (1:350) (Sigma) 
for the detection of arteries and arterioles. Incubation with 
anti-rabbit AlexaFluor 568 (1:200, 2 h) was performed on 
the next day, followed by endothelial cell labelling using 
biotinylated lectin (1:250, 30 min) (Vector Biolabs), visu-
alised using AMCA streptavidin (1:100, 1 h) (Vector Bio-
labs). Tiled images of coronal cortical cross-sections were 
obtained using Zeiss LSM 800 confocal microscope.
Data analysis
Differences between the experimental groups were analysed 
using GraphPad Prism 6 software. Comparisons were made 
using analysis of variance (ANOVA) followed by Sidak’s p 
value correction for multiple comparisons or Student’s t test, 
as appropriate. Data are reported as individual values and 
means ± standard error of the means (SEM).
Results
In rats, MCAO lasting 90 min led to the development of 
cerebral infarcts averaging 36.5 ± 6.3% (n = 7) of the 
hemisphere volume (Fig. 1b). RIC induced by 4 episodes 
of unilateral femoral ischaemia/reperfusion markedly 
reduced the cerebral infarct size (8.2 ± 3.4%; p = 0.019) 
(Fig. 1b) and improved the neurological score (from 10 to 
2 on the 22-point scale; p = 0.001) (Fig. 1c). The neuro-
protective effect of RIC was abolished by systemic GLP-
1R blockade with Ex9 (Fig. 1b, c). In this experimental 
group (MCAO + Ex9 + RIC) the cerebral infarct size was 
32.8 ± 6.1% (p > 0.9 vs 36.5 ± 6.3% in the MCAO + sham-
RIC group) and the neuroscore was 10 ± 2 (p > 0.9 vs 10 ± 1 
in the MCAO + sham-RIC group). Ex9 had no effect on the 
infarct size and behavioural neurological traits in animals 
subjected to MCAO and sham-RIC procedure (Fig. 1b, c). 
These data suggested that signalling via GLP-1Rs is criti-
cally important for RIC-induced neuroprotection against 
ischaemic stroke.
GLP-1 may act on brain vessels and aid neuroprotection 
by improving/maintaining cerebral blood flow in the regions 
surrounding the affected brain area. To test this hypothesis, 
we next determined the expression of GLP-1R by the brain 
vasculature and investigated the effects of GLP-1R activa-
tion on cerebral arterioles and capillaries. In the cerebral 
cortex of the GLP-1R reporter mice, expression of GLP-1R 
was found to be largely confined to arteriolar smooth muscle 
and endothelial cells (Fig. 2a, b). Patchy GLP-1R expres-
sion was detected in cells associated with isolated capillaries 
and veins (Fig. 2c, d). It was found that in the mouse brain 
69 ± 17% of cortical arterioles, 2 ± 0.2% of capillaries and 
6 ± 6% of venules express the GLP-1R.
Next, the effect of GLP-1R activation on cortical arte-
rioles and capillaries was determined in acute brain slices. 
Vessels in brain slices are lacking tone and are typically fully 
dilated (due to the absence of the perfusion pressure), there-
fore, studies of cerebrovascular responses ex vivo require the 
application of the constricting agents [65]. We used lactate 
as a constricting agent because the release of this metabo-
lite increases in hypoxic and ischaemic conditions [43, 44, 
57]. In a series of preliminary trials, we found that lactate 
in concentrations of 5 mM and 20 mM in osmolarity-con-
trolled aCSF reduced the diameter of cortical arterioles after 
20 min of application by 24 ± 4% and 23 ± 1%, respectively 
(p < 0.001) (Fig. 3a, b). Therefore, in all the subsequent 
experiments we used 5 mM lactate to constrict the cortical 
arterioles.
In the presence of 5 mM lactate, bath application of 
GLP-1R agonist Ex4 (100 nM) caused significant dilations 
of cortical arterioles (p = 0.031), effectively reversing lac-
tate-induced constrictions (Fig. 3a, c). The effect of Ex4 on 
cortical arterioles was not affected by L-NAME (100 µM) 
(Fig. 3d), suggesting that GLP-1R-mediated cerebrovascular 
responses are not mediated by the release and actions of 
nitric oxide. However, arteriolar dilations induced by Ex4 
were prevented by the broad-spectrum adenylate cyclase 
inhibitor SQ22536 (100 µM) (Fig. 3e), indicating that the 
vascular effects of GLP-1R activation are mediated by a 
cAMP/PKA signalling pathway.
Next the effect of Ex4 on cerebral blood vessels was 
investigated in the ex  vivo model of ischaemic stroke, 
induced by oxygen and glucose deprivation of cortical brain 
slices. Similarly to the effect of lactate, OGD led to strong 
constrictions of cortical vessels (Fig. 4a, b). OGD reduced 
cortical capillary diameter by 13 ± 6% (p = 0.019) and arteri-
olar diameter by 27 ± 4% (p < 0.001) 10 min after the stimu-
lus onset. Ex4 had no effect on OGD-induced reduction in 
capillary diameter (p = 0.74; Fig. 4d), but reversed the effect 
of OGD on cortical arterioles (p < 0.001; Fig. 4a, c). The 
dilatory effect of Ex4 on cortical arterioles in conditions of 
OGD was blocked by Ex9 (1 µM; Fig. 4c), confirming that 
the effect of Ex4 is specific and mediated by GLP-1Rs.
To determine the effect of GLP-1R activation on cerebral 
blood flow in vivo, changes in brain tissue  PO2 induced by 
systemic administration of Ex4 (10 μg  kg−1, intravenously) 
were recorded in anaesthetised and artificially ventilated 
rats. It was found that Ex4 induces lasting increases in 
brain tissue  PO2 (Fig. 5). Ex4 increased  PtO2 in the cerebral 
cortex from 22.0 ± 1.6 mmHg to 30.4 ± 2.9 mmHg (38% 
increase; p = 0.007, n = 6) 30 min after the injections, and 
this effect was sustained for at least 3 h (Fig. 5). Since in this 
model changes in brain tissue  PO2 parallel changes in brain 
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perfusion [18], these data indicate that activation of GLP-
1Rs increases cerebral blood flow.
Discussion
Powerful innate mechanisms of inter-organ protection are 
activated by remote ischaemic conditioning which can be 
established by cycles of ischaemia/reperfusion applied to 
an organ/tissue distant from the organ being protected [13]. 
Numerous experimental studies demonstrated the efficacy 
of RIC in protecting the brain and the heart against ischae-
mia/reperfusion injury. We previously proposed that the 
signalling mechanisms from the remote organ to the heart 
involve sensory (afferent) innervation of the peripheral tissue 
undergoing RIC, autonomic parasympathetic innervation of 
the visceral organs, and the release and actions of GLP-1 
[5, 6, 62, 63]. The results of the present study suggest that 
RIC-induced neuroprotection against ischaemic stroke is 
mediated by a similar mechanism involving GLP-1R-medi-
ated signalling. This conclusion is supported by the central 
finding of the present study that the highly selective GLP-
1R antagonist Ex9 blocks the neuroprotective effect of RIC.
Several studies reported the neuroprotective effects of 
GLP-1 and GLP-1R agonists in preclinical models of stroke 
[9, 21, 45]. Yet, the mechanisms underlying the GLP-1R-me-
diated neuroprotection are not fully understood. There is evi-
dence that treatment with GLP-1R agonists increases GLP-
1R expression, increases the level of the neurotrophic factor 
BDNF, protects the blood–brain barrier through MMP-9 
regulation, decreases microglial activation, oxidative stress 
and the release of apoptotic factors [41, 48, 50, 51, 78, 85]. 
Here we tested the hypothesis that GLP-1 actions reduce 
ischaemic brain tissue damage via activation of GLP-1R on 
cerebral vasculature leading to the improvement of brain 
blood flow. The data obtained support this hypothesis by 
Fig. 2  GLP-1 receptor expres-
sion in cortical blood vessels. 
Representative images of 
coronal sections of the cerebral 
cortex of glp1r-Cre/ROSA26-
tdRFP mouse, immunostained 
for red fluorescent protein (red), 
illustrating GLP-1 receptor 
expression associated with pen-
etrating cortical arteriole (a), 
parenchymal arteriole (b), capil-
lary (c), and venule (d). Arte-
riole smooth muscle cells were 
labelled by immunohistochemi-
cal detection of smooth muscle 
actin (SMA, green). Endothelial 
cells were labelled with lectin 
(blue). Arrows point to other 
cortical GLP-1 receptor-positive 
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showing that GLP-1R are expressed by the cells lining corti-
cal arterioles and that the GLP-1R agonist Ex4 effectively 
reverses the constriction of these arterioles induced by lac-
tate or simulated ischaemia (OGD) ex vivo and increases the 
cerebral blood flow in vivo. Collectively these data suggest 
that vascular mechanisms are likely to mediate the neuro-
protective effects downstream of GLP-1R activation. The 
importance of preserving microvascular flow in the context 
of cardioprotection against myocardial ischaemia/reperfu-
sion injury had been recently highlighted [32].
GLP-1Rs have been shown to be expressed by the arte-
rial smooth muscle cells in the peripheral vasculature [71]. 
The vasodilatory effect of GLP-1 on the aorta was shown to 
be mediated through glucagon signalling,  KATP channels, 
PKA phosphorylation [27, 30, 73] and increased NO pro-
duction [3]. A recent study demonstrated that Ex4 causes 
dilation of retinal capillaries and this effect is mediated by 
NO [86]. The data obtained in this study show that the vaso-
dilatory effect of GLP-1R activation on cortical arterioles is 
mediated by cAMP and is independent of NO production. 
That cAMP mediates the effects of a GLP-1 analogue is not 
surprising considering that GLP-1R is a well-characterized 









































































































































Fig. 3  GLP-1 receptor activation dilates cortical arterioles. a Rep-
resentative DIC images illustrating a cortical arteriole response to 
5 mM lactate and GLP-1 receptor agonist Exendin-4 (Ex4; 100 nM), 
applied in the presence of lactate, recorded in a coronal slice of a rat 
cerebral cortex. The yellow dashed line outlines the edge of the ves-
sel; the length of the white dotted line illustrates the smallest diam-
eter of the vessel recorded during the course of the experiment. Scale 
bar = 10 µm. b Summary data illustrating changes in the diameter of 
cortical arterioles recorded over time and peak arteriolar responses 
induced by lactate applied in concentrations of 5 or 20 mM. c Sum-
mary data illustrating the effect of Ex4 on the diameter of cortical 
arterioles pre-constricted with lactate (5 mM). Lactate-evoked arteri-
olar constrictions were effectively reversed by Ex4. d Summary data 
illustrating the effect of Ex4 on the diameter of cortical arterioles pre-
constricted with lactate (5 mM) in the presence of nitric oxide syn-
thase inhibitor l-NAME (100 µM). l-NAME had no effect on Ex4-
induced arteriolar dilations. e, Summary data illustrating the effect 
of Ex4 on the diameter of cortical arterioles pre-constricted with lac-
tate (5 mM) in the presence of adenylate cyclase inhibitor SQ22536 
(100  µM). SQ22536 prevented the arteriolar dilations induced by 
Ex4. Numbers in parentheses indicate the numbers of slices obtained 
from the same number of animals (biological replicates). Individual 
data and/or means ± SEM are shown. p values—paired t test
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Fig. 4  GLP-1 receptor activation dilates cortical arterioles in the 
ex  vivo model of ischaemic stroke. a Representative DIC images 
illustrating a cortical arteriole response to oxygen and glucose dep-
rivation (OGD) followed by GLP-1 receptor agonist Exendin-4 (Ex4; 
100 nM) applied in conditions of OGD, recorded in a coronal slice of 
a rat cerebral cortex. Scale bar = 10 µm. b Summary data illustrating 
changes in the diameter of cortical arterioles recorded over time and 
peak arteriolar responses induced by OGD. c Summary data illustrat-
ing the effect of Ex4 on the diameter of cortical arterioles in condi-
tions of OGD in the absence and presence of GLP-1 receptor antag-
onist Ex9 (1  µM). Arteriolar constrictions induced by OGD were 
reversed by Ex4. d Summary data illustrating peak changes in the 
diameter of cortical capillaries induced by OGD and after application 
of Ex4 in conditions of OGD. Numbers in parentheses indicate the 
numbers of slices obtained from the same number of animals (bio-
logical replicates). Individual data and/or means ± SEM are shown. p 
values—paired (b, c) or unpaired (d) t test
Fig. 5  GLP-1 receptor activa-
tion increases cerebral blood 
flow in vivo. a Representative 
raw traces of changes in brain 
tissue partial pressure of oxygen 
 (PtO2), heart rate (HR) and 
mean arterial blood pressure 
(MAP) after intravenous infu-
sion of saline (0.1 ml) followed 
by GLP-1 receptor agonist 
Exendin-4 (Ex4; 10 μg  kg−1, 
0.1 ml volume) in an anaesthe-
tised and artificially venti-
lated rat. Cx cerebral cortex. 
b Summary data illustrating 
changes in brain  PtO2 recorded 
continuously for 30 min after 
the intravenous infusion of 
saline or Ex4 (10 μg  kg−1) in 
anaesthetised and artificially 
ventilated rats (n = 6). c Sum-
mary data illustrating the lasting 
effect of GLP-1R activation on 
brain  PtO2 in a separate cohort 
of animals (n = 5). 5 min-long 
recordings of  PtO2 were taken 
at baseline and then 1,2, and 3 h 
after the administration of Ex4 
(10 μg  kg−1)
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In GLP-1R reporter mice, we found that most vascular 
GLP-1R expression in the cortex is associated with arteri-
oles with no significant receptor expression detected in cells 
associated with brain capillaries and venules. These data are 
fully consistent with the results of single-cell RNA sequenc-
ing of brain vasculature [80]. Dilation of cortical arterioles 
induced by GLP-1R activation is likely to lessen the impact 
of the neurotoxic effects associated with impaired cerebral 
perfusion in stroke, as early improved perfusion is beneficial 
for better functional outcomes [28]. Indeed, maintaining/
restoring blood supply in the penumbra has been shown to 
reduce the size and severity of cerebral infarcts [4]. The 
conclusions of this study are also supported by the recent 
evidence obtained in rodent models showing a marked 
reduction of cerebral blood flow after MCAO and improved 
collateral circulation in response to RIC [46, 55]. However, 
one of the limitations of our study is that the effect of RIC 
on collateral circulation was not assessed in conditions of 
systemic GLP-1R blockade with Ex9.
The source of GLP-1 that acts on GLP-1Rs expressed 
by cortical arterioles and mediates RIC-induced neuropro-
tection against ischaemic stroke remains to be determined. 
In our previously proposed model of RIC-induced cardio-
protection, we suggested that cycles of remote ischaemia/
reperfusion activate tissue nociceptors [5] that project to 
the CNS, leading to activation of a specific group of vagal 
preganglionic neurons [62] that innervate the gut [63], and 
upon activation stimulate the release of GLP-1 into the sys-
temic circulation, culminating in cardioprotective action of 
GLP-1 on the heart [6, 81]. It is plausible that the same 
reflex mechanism underlies RIC-induced neuroprotection: 
RIC stimulates GLP-1 secretion by enteroendocrine cells of 
the gut, leading to GLP-1 release into the systemic circula-
tion and its action on the brain vasculature. However, most 
of the intestinally-derived GLP-1 is believed to be rapidly 
degraded and low levels of GLP-1 are usually detected in the 
systemic circulation. For example, in a study showing that 
GLP-1R activation has protective effects on the endothelium 
in obese rats and patients, only modest increases in plasma 
GLP-1 were reported [67]. Yet, there is also evidence that 
the lasting effects of GLP-1 may persist for some time even 
when the circulating levels of the hormone return back to 
the normal level [38].
It is also conceivable that RIC stimulates the release 
of GLP-1 within the brain by the preproglucagon neurons 
that reside in the brainstem and have projections to the 
forebrain [16, 40, 53]. This distinct population of GLP-
1-producing neurons reside in the dorsal vagal complex 
[53] and in close proximity to the pool of vagal pregan-
glionic neurones that are critically important for RIC-
induced effects [62]. Conceivably, afferent inputs from 
the peripheral organ/tissue undergoing RIC activate both 
neighbouring populations of brainstem neurons leading 
to simultaneous increases in vagal activity and release 
of GLP-1 in the CNS. However, the brainstem PPG neu-
rones have no direct projections to the cerebral cortex and 
GLP-1 receptors are not widely expressed by cortical neu-
rons [16]. Therefore, it seems unlikely that RIC-induced 
neuroprotection is mediated by direct actions of GLP-1 on 
brain neurons. Collectively, the data obtained in this study 
point to the importance of the mechanism that modulates 
cerebral blood flow and is mediated by vascular GLP-1Rs 
located on the luminal side of the blood–brain barrier.
Despite strong pre-clinical evidence of the effectiveness 
of RIC in protecting the heart and the brain against ischae-
mia/reperfusion injury, it has failed to translate into a clin-
ical treatment of myocardial infarction or stroke. Studies 
conducted in young and healthy experimental animals 
reported that RIC can markedly reduce cortical infarcts 
[10, 72, 84]. Yet, clinical data show no major beneficial 
effect of RIC on stroke outcomes [68], although with some 
suggestion of reduced recurrent strokes with intracerebral 
artery stenosis treatment, and decreased stroke severity 
with carotid stenosis [69]. We previously demonstrated 
that RIC is critically dependent on autonomic parasympa-
thetic mechanisms [62] and it is plausible that its clinical 
efficacy is compromised by the inability of many patients 
to recruit vagal activity. As we reasoned in our earlier 
publications [7, 25, 26, 63] and reported supporting evi-
dence [1, 56], vagal tone decreases with age and could 
be severely diminished or even absent in many disease 
states, rendering many patients unable to recruit innate 
mechanisms of inter-organ protection. If GLP-1 is a com-
mon mediator of cardio- and neuroprotection induced by 
RIC, then administration of GLP-1 stable analogues may 
offer a better therapeutic solution for the treatment of acute 
myocardial infarction and ischaemic stroke, especially in 
patients with autonomic dysfunction. Indeed, exenatide 
(synthetic Ex4) had been shown to reduce the myocar-
dial injury in patients with myocardial infarction [54], 
although the results of a recent clinical trial studying the 
individual effects of RIC, exenatide, and their combina-
tion (COMBAT-MI trial) showed no effect of these treat-
ments on infarct size [22]. However, as it was highlighted 
[11] in that study neither the dose given, nor the plasma 
concentration of exenatide were known to determine the 
bioavailability of the drug at the time of treatment.
In conclusion, this study shows that GLP-1R activation 
mediates neuroprotection against ischaemic stroke estab-
lished by remote ischaemic conditioning. The neuroprotec-
tion induced by GLP-1 is likely to be mediated via its action 
on cortical arterioles and improved perfusion in the areas 
surrounding the infarcted brain tissue.
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